Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa-2a plus ribavirin with peer-supported DOT in active injecting drug users with chronic hepatitis C
ACTRN12608000400369Phase 4Recruiting
- Sponsor
- Dr Joe Sasadeusz
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by Dr Joe Sasadeusz. Primary endpoints: Therapy compliance by DOT attendance and Therapy completion by drug exposure. Started Aug 2008; status: recruiting.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12608000400369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000400369.